BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 16391155)

  • 1. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
    Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of lesions with a high risk of stenosis. Comparative study in 300 patients of rapamycin- and Paclitaxel-eluting polymer-based stents, and bare metal stents].
    de la Torre Hernández JM; Sainz Laso F; Ruisánchez C; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2005 Mar; 58(3):262-9. PubMed ID: 15766448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions.
    Iofina E; Langenberg R; Blindt R; Kühl H; Kelm M; Hoffmann R
    Am J Cardiol; 2006 Oct; 98(8):1022-7. PubMed ID: 17027564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.
    Hausleiter J; Kastrati A; Wessely R; Dibra A; Mehilli J; Schratzenstaller T; Graf I; Renke-Gluszko M; Behnisch B; Dirschinger J; Wintermantel E; Schömig A;
    Eur Heart J; 2005 Aug; 26(15):1475-81. PubMed ID: 15975990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
    Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
    Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents.
    Peters S; Behnisch B; Heilmann T; Richter C
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):91-5. PubMed ID: 19502256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.
    Colombo A; Drzewiecki J; Banning A; Grube E; Hauptmann K; Silber S; Dudek D; Fort S; Schiele F; Zmudka K; Guagliumi G; Russell ME;
    Circulation; 2003 Aug; 108(7):788-94. PubMed ID: 12900339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry.
    Buellesfeld L; Gerckens U; Mueller R; Schmidt T; Grube E
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):173-7. PubMed ID: 16144017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
    Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease.
    Lansky AJ; Costa RA; Mooney M; Midei MG; Lui HK; Strickland W; Mehran R; Leon MB; Russell ME; Ellis SG; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1180-5. PubMed ID: 15837246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.